Medical Device News Magazine

Vios Fertility Institute – St. Louis and TMRW Life Sciences Launches State-of-the-Art Cryo Management Technology for Fertility Specimens

About Medical Device News Magazine

About Medical Device News Magazine. We are a digital publication founded in 2008 located in the United States.

Advertise with Medical Device News Magazine! Join Our #1 Family of Advertisers!

We pride ourselves on being the best-kept secret when it comes to distributing your news! Our unique digital approach enables us to circulate your...

Vios Fertility Institute (Vios) – a global leader in fertility treatment, research and science – expands their network partnership with TMRW Life Sciences (TMRW) to implement a state-of-the-art cryo management solution for fertility specimens at their St. Louis clinic/lab on January 26, 2022.

TMRW’s technology provides the world’s first and only fully automated specimen management platform (CryoRobot) that identifies, tracks, and manages frozen eggs and embryos – central to almost every IVF journey.  Vios Fertility Institute’s Chicago lab was the first in the world to adopt this revolutionary technology in early 2021.

“At Vios, we are committed to being an innovative fertility clinic and ensuring patients benefit from the technologies that protect the embryos and eggs they worked so hard to preserve to build their families,” explains Dr. Amber Cooper, Medical and IVF Practice Director of Vios Fertility Institute -St. Louis.  “Our company was the first in the world to embrace this technology because we know how important peace of mind and this protection is for patients.  While human error with manual tanks is rare, even one instance can be catastrophic which is why this new technology-driven platform that delivers digital tracking and thousands of daily safety checks is game-changing for our field.”

St. Louis couples Kadie & Mark Brown, and Beth & Daren Berry have received fertility treatments from Vios – St. Louis will be the first patients to begin storing frozen embryos in TMRW’s CryoRobot.

“While we are preparing for the birth of our second child this April, TMRW’s technology provides us with peace of mind knowing that our remaining embryos are being monitored 24/7,” adds Kadie Brown.

“We are thrilled to learn that Vios will be implementing TMRW’s cryo management system and that our embryos will be cared for using this new technology,” explains Beth Berry.  “Vios is always on the forefront of the latest research and techniques, which is one of the many reasons we chose Dr. Cooper and her team for our fertility journey.”

Since the birth of the first IVF baby over 40 years ago, reproductive medicine has progressed with numerous breakthroughs and discoveries, but the management of frozen specimens has not seen the same level of advancement. Current methods are manual, analog, and labor-intensive, challenged to keep up with increasing levels of demand for fertility services. TMRW brings technology and automation to the process, providing digital identification and tracking of specimens and complete traceability of the frozen eggs and embryos of every patient. TMRW’s proprietary ‘Overwatch’ provides 24/7 monitoring giving complete assurance as to the safety of specimens under clinic care. The Vios network embraces the technological and engineering advances that the TMRW platform provides and is ushering in a new and improved standard of care in the IVF lab.

 

“We are proud to expand our partnership with Vios Fertility, a global fertility pioneer, to provide this cutting-edge solution and deliver unparalleled transparency, traceability and security, dramatically reducing risk and providing peace of mind during what is a deeply personal journey for fertility patients,” said Tara Comonte, CEO of TMRW. “TMRW’s solution enables clinics to scale to meet the growing demand for fertility services and safely care for the resulting exponential increase in the number of specimens under their management.”

The TMRW cryo specimen management platform key features include:

  • Proprietary labware with industry-leading thermal properties and fully automated robotic storage (‘CryoRobot’) to maintain safe cryogenic temperatures for specimens at all times.
  • Unique digital identification for each patient using advanced RFID labware, enabling clinics to identify and track specimens, creating an unbreakable track and trace audit trail.
  • 24/7, remote monitoring (‘Overwatch’) performs thousands of system performance checks every day, enabling the system to proactively predict clinic and specimen safety.
  • Fully encrypted, HIPAA-compliant software, providing the highest level of privacy and security to both patient and clinic data.

Vios Fertility Institute has three locations in the St. Louis/Southern Illinois region including: Creve Coeur, MO (clinic/lab) 347 North Lindbergh Boulevard, O’Fallon, MO (clinic) 5551 Winghaven Blvd. Suite 230, and Swansea, IL (clinic) 6 Bronze Pointe.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Other News

Shoulder Innovations Further Strengthens IP Portfolio in Key Areas with Recent Patent Grants

"These recent grants further strengthen key patent families that are foundational to our technology, and we are pleased the USPTO continues to recognize our meaningful innovation in the shoulder arthroplasty segment," said Rob Ball, CEO of Shoulder Innovations. "This noteworthy expansion of our IP position represents the culmination of over 10 years of research and development, and we are proud of our team for their continued dedication to creating practical solutions for shoulder surgeons and advancing patient outcomes."

Radical Catheter Technologies Presents Analysis of Disruptive, Recently FDA-Cleared Endovascular Technology at the Society of NeuroInterventional Surgery 21st Annual Meeting

This new catheter, the first product commercialized from this novel technology platform, is designed to enable access to the blood vessels in the brain for both femoral and radial access. A multi-center analysis of this disruptive technology is being presented today at Society of NeuroInterventional Surgery 21st annual meeting. In addition, the Company confirmed the closing of a $20 million financing round led by NeuroTechnology Investors, which will be used to scale the company and expand the Radical platform notes Radical Catheter Technologies.

Rapid Medical™ Completes Initial Neurovascular Cases in the USA Following FDA Clearance of Its Active Access Solution

“With DRIVEWIRE, our design goal was to bring new levels of access and control to the interventional suite while improving best-in-class guidewires,” comments Giora Kornblau, Chief Technology Officer at Rapid Medical. “When physicians are looking for technologies that increase the clinical possibilities and safety for the patient, we want Rapid to be the first place they look.”